Pharming Group Nv Stock Fundamentals
| PHGUF Stock | USD 0.95 0.12 11.21% |
Pharming Group NV fundamentals help investors to digest information that contributes to Pharming Group's financial success or failures. It also enables traders to predict the movement of Pharming Pink Sheet. The fundamental analysis module provides a way to measure Pharming Group's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Pharming Group pink sheet.
Pharming |
Pharming Group NV Company Return On Equity Analysis
Pharming Group's Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.
Current Pharming Group Return On Equity | 0.17 |
Most of Pharming Group's fundamental indicators, such as Return On Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Pharming Group NV is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
| Competition |
Based on the latest financial disclosure, Pharming Group NV has a Return On Equity of 0.1669. This is 100.7% lower than that of the Healthcare sector and 100.46% lower than that of the Biotechnology industry. The return on equity for all United States stocks is 153.84% lower than that of the firm.
Pharming Group NV Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Pharming Group's current stock value. Our valuation model uses many indicators to compare Pharming Group value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Pharming Group competition to find correlations between indicators driving Pharming Group's intrinsic value. More Info.Pharming Group NV is considered to be number one stock in return on equity category among related companies. It is considered to be number one stock in return on asset category among related companies reporting about 0.39 of Return On Asset per Return On Equity. The ratio of Return On Equity to Return On Asset for Pharming Group NV is roughly 2.60 . Comparative valuation analysis is a catch-all model that can be used if you cannot value Pharming Group by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Pharming Group's Pink Sheet. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Pharming Group's earnings, one of the primary drivers of an investment's value.Pharming Return On Equity Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Pharming Group's direct or indirect competition against its Return On Equity to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Pharming Group could also be used in its relative valuation, which is a method of valuing Pharming Group by comparing valuation metrics of similar companies.Pharming Group is currently under evaluation in return on equity category among related companies.
Pharming Fundamentals
| Return On Equity | 0.17 | |||
| Return On Asset | 0.0643 | |||
| Profit Margin | 0.15 % | |||
| Operating Margin | 0.18 % | |||
| Current Valuation | 721.19 M | |||
| Shares Outstanding | 652.41 M | |||
| Shares Owned By Insiders | 1.97 % | |||
| Shares Owned By Institutions | 16.43 % | |||
| Price To Earning | 18.97 X | |||
| Price To Book | 3.94 X | |||
| Price To Sales | 3.69 X | |||
| Revenue | 167.68 M | |||
| Gross Profit | 177.73 M | |||
| EBITDA | 41.22 M | |||
| Net Income | 16 M | |||
| Cash And Equivalents | 189.96 M | |||
| Cash Per Share | 0.29 X | |||
| Total Debt | 122.65 M | |||
| Debt To Equity | 0.75 % | |||
| Current Ratio | 5.22 X | |||
| Book Value Per Share | 0.30 X | |||
| Cash Flow From Operations | 37.84 M | |||
| Earnings Per Share | 0.05 X | |||
| Target Price | 24.89 | |||
| Number Of Employees | 277 | |||
| Beta | 0.98 | |||
| Market Capitalization | 880.76 M | |||
| Total Asset | 350.55 M | |||
| Retained Earnings | (273 M) | |||
| Working Capital | 23 M | |||
| Current Asset | 41 M | |||
| Current Liabilities | 18 M | |||
| Z Score | 4.2 | |||
| Net Asset | 350.55 M |
About Pharming Group Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Pharming Group NV's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Pharming Group using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Pharming Group NV based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.Pharming Group N.V., a biopharmaceutical company, develops and commercialize protein replacement therapies and precision medicines for the treatment of rare diseases and unmet medical needs in the United States, Europe, and internationally. Pharming Group N.V. is headquartered in Leiden, the Netherlands. Pharming Grp operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 277 people.
Becoming a Better Investor with Macroaxis
Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as Pharming Group NV using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.Build Optimal Portfolios
Align your risk with return expectations
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Pharming Group NV. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in employment. You can also try the Pattern Recognition module to use different Pattern Recognition models to time the market across multiple global exchanges.
Complementary Tools for Pharming Pink Sheet analysis
When running Pharming Group's price analysis, check to measure Pharming Group's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pharming Group is operating at the current time. Most of Pharming Group's value examination focuses on studying past and present price action to predict the probability of Pharming Group's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pharming Group's price. Additionally, you may evaluate how the addition of Pharming Group to your portfolios can decrease your overall portfolio volatility.
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA |